These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3465128)

  • 41. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A randomized controlled study of adjuvant immunotherapy with N-CWS for head and neck malignancies].
    Sakai S; Itoh M; Matsunaga T; Yoshida J; Sato T; Miyahara Y; Matsunaga T; Hyoh Y; Ohyama K; Katsuta K
    Gan No Rinsho; 1985 Sep; 31(11):1353-61. PubMed ID: 4068237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma.
    Dasgupta S; Tripathi PK; Qin H; Bhattacharya-Chatterjee M; Valentino J; Chatterjee SK
    Oral Oncol; 2006 Mar; 42(3):306-16. PubMed ID: 16321566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches.
    Uppaluri R; Bell RB; Sunwoo JB
    Oral Oncol; 2016 Jul; 58():49-51. PubMed ID: 27238227
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck.
    Sirianni N; Ha PK; Oelke M; Califano J; Gooding W; Westra W; Whiteside TL; Koch WM; Schneck JP; DeLeo A; Ferris RL
    Clin Cancer Res; 2004 Oct; 10(20):6929-37. PubMed ID: 15501971
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
    Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
    Strome SE; Dong H; Tamura H; Voss SG; Flies DB; Tamada K; Salomao D; Cheville J; Hirano F; Lin W; Kasperbauer JL; Ballman KV; Chen L
    Cancer Res; 2003 Oct; 63(19):6501-5. PubMed ID: 14559843
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunology of head and neck cancer: perspectives.
    Cortesina G; Sacchi M; Galeazzi E; De Stefani A
    Head Neck; 1993; 15(1):74-7. PubMed ID: 8416863
    [No Abstract]   [Full Text] [Related]  

  • 50. [Recent treatment modality for advanced head and neck carcinomas].
    Tsukuda M
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1657-64. PubMed ID: 9757189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The influence of immunologic responsiveness on head and neck cancer. Therapeutic implications.
    Woods JE
    Plast Reconstr Surg; 1975 Jul; 56(1):77-80. PubMed ID: 1144550
    [No Abstract]   [Full Text] [Related]  

  • 52. The effects of smoking on immunocompetence.
    Chretien PB
    Laryngoscope; 1978 Jan; 88(1 Pt 2 Suppl 8):11-3. PubMed ID: 201813
    [No Abstract]   [Full Text] [Related]  

  • 53. Adjuvant immunotherapy for patients with melanoma.
    Myers JN
    Head Neck; 1998 May; 20(3):270. PubMed ID: 9570634
    [No Abstract]   [Full Text] [Related]  

  • 54. Head and Neck Cancer Control Network completes five years in Wisconsin.
    Buchanan-Davidson DJ
    Wis Med J; 1979 Jul; 78(7):33-4. PubMed ID: 483853
    [No Abstract]   [Full Text] [Related]  

  • 55. [Oncoimmunology in old age].
    Wigand MC; Jeske S; Hahn J; Doescher J; Laban S; Hoffmann TK; Schuler PJ
    HNO; 2020 Mar; 68(3):177-183. PubMed ID: 31559466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Head and neck surgeons at the vanguard of immunotherapy.
    Bell RB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 May; 123(5):517-518. PubMed ID: 28407982
    [No Abstract]   [Full Text] [Related]  

  • 57. Evaluation of immunocompetence and "immunostaging".
    Ablin RJ; Guinan PD; Khin W; Zamora S
    South Med J; 1979 Oct; 72(10):1350-1. PubMed ID: 573499
    [No Abstract]   [Full Text] [Related]  

  • 58. Head and neck cancer: the year 2000.
    Goepfert H
    Cancer Treat Res; 1995; 74():283-92. PubMed ID: 7779621
    [No Abstract]   [Full Text] [Related]  

  • 59. Preface for the special issue of "Immunotherapy for head and neck cancers: Current landscapes, emerging biomarkers, and future directions".
    Lou PJ
    Head Neck; 2019 Oct; 41 Suppl 1():3. PubMed ID: 31573751
    [No Abstract]   [Full Text] [Related]  

  • 60. 4th Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer. September 8-11, 1994. Abstracts.
    Head Neck; 1994; 16(5):471-522. PubMed ID: 7960748
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.